Talquetamab Clinical Trials
19 recruitingDrug
Phase 212Phase 14Phase 32
Showing 1–19 of 19 trials
Recruiting
Phase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Noffar Bar50 enrolled2 locationsNCT06993675
Recruiting
Phase 2
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Multiple Myeloma
SCRI Development Innovations, LLC100 enrolled17 locationsNCT05972135
Recruiting
Phase 2
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
Multiple Myeloma (MM)
European Myeloma Network B.V.150 enrolled29 locationsNCT07107529
Recruiting
Phase 2
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Hematological Malignancies
Janssen Research & Development, LLC510 enrolled78 locationsNCT04634552
Recruiting
Phase 2
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Multiple Myeloma
Janssen Research & Development, LLC210 enrolled38 locationsNCT06500884
Recruiting
Phase 3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Janssen Research & Development, LLC1,590 enrolled263 locationsNCT05552222
Recruiting
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
Janssen-Cilag Ltd.900 enrolled68 locationsNCT06285318
Recruiting
Phase 1
Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
Relapsed Refractory Multiple Myeloma (RRMM)
Massachusetts General Hospital25 enrolled3 locationsNCT07032714
Recruiting
Phase 3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Multiple Myeloma
Janssen Research & Development, LLC795 enrolled242 locationsNCT06208150
Recruiting
Phase 1
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Multiple MyelomaRefractory Multiple MyelomaRelapsed Multiple Myeloma
Alfred Chung, MD32 enrolled1 locationNCT06348108
Recruiting
Phase 2
A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
Multiple Myeloma
Memorial Sloan Kettering Cancer Center17 enrolled7 locationsNCT06066346
Recruiting
Phase 2
Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
Multiple Myeloma
Carl Ola Landgren, MD, PhD50 enrolled1 locationNCT06100237
Recruiting
Phase 1
Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma
Refractory Multiple MyelomaRelapse Multiple Myeloma
Medical College of Wisconsin31 enrolled1 locationNCT07093554
Recruiting
Phase 2
Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
Multiple Myeloma in Relapse
Larysa Sanchez23 enrolled1 locationNCT06827860
Recruiting
Phase 2
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
Multiple Myeloma
University of Heidelberg Medical Center160 enrolled11 locationsNCT05695508
Recruiting
Phase 1Phase 2
External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease
Multiple MyelomaExtramedullary Disease in Multiple Myeloma
City of Hope Medical Center20 enrolled1 locationNCT06572605
Recruiting
Phase 2
Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma
Multiple MyelomaPost Stem Cell Transplant
Stanford University20 enrolled1 locationNCT06461988
Recruiting
The Norwegian Immunotherapy in Multiple Myeloma Study
St. Olavs Hospital400 enrolled23 locationsNCT06855121
Recruiting
Phase 2
Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
Multiple Myeloma
North Estonia Medical Centre50 enrolled7 locationsNCT06505369